Fenestra HDVC™ is a biomimetic nanoemulsion contrast agent designed to deliver exceptional soft tissue visualization in microCT imaging for preclinical research. Engineered to closely mimic naturally circulating chylomicron remnants, it is the only hepatocyte-selective contrast agent available for preclinical use, allowing researchers to achieve high-resolution imaging of organs, vascular systems, and soft tissues across PET-CT and SPECT-CT modalities. Its modified vitamin E-based formulation makes it safe and non-toxic, rendering it well-suited for longitudinal in vivo studies. Fenestra HDVC™ can be administered either intravenously (IV) or intraperitoneally (IP) — with IV injection providing immediate vascular contrast, while IP injection offers a convenient alternative with blood pool visualization achievable at 24 hours post-injection and liver and spleen contrast at 48 hours. In oncology research, it enhances the visualization of liver and pancreatic tumors — including small masses — while also supporting detailed organ imaging for drug biodistribution studies and the evaluation of therapeutic interventions. Its versatility makes it a valuable tool across a broad range of preclinical applications, from cancer research and drug development to therapy assessments.
Interested in testing out Fenestra HDVC for liver tumors? Ask us about our CRO services for scanning excised livers with microCT.
USD $405
